Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology – 2021Realização: Departamento de Imagem Cardiovascular (DIC) da Sociedade Brasileira de Cardiologia (SBC) eendossado pela Sociedad Interamericanana de Imágenes

Position Statement on the Use of Myocardial Strain in Cardiology Routines by the BrazilianSociety of Cardiology’s Department Of Cardiovascular Imaging – 2023Realização: Departamento de Imagem Cardiovascular da Sociedade Brasileira de

Cardiac amyloidosis is a classic example of an infiltrativedisease whose predominant phenotype is characterized by ahypertrophic pattern of myocardial involvement.¹,² The mostrelevant studies—both those focused on the development ofdisease-modifying therapies

Background The diagnosis of cardiac amyloidosis (CA) ischallenging owing to vague symptomatology and nonspecific echocardiographic findings.Objective To describe regional patterns in longitudinalstrain (LS) using two-dimensional speckle-trackingechocardiography in CA and to

Recent-onset cardiomyopathy represents a clinically dynamic and potentially reversible clinical framework of non-ischaemiccardiomyopathy, characterized by high variability in left ventricular (LV) function and arrhythmic risk. This clinical consensusstatement provides a

Technetium-99m bone scintigraphy has revolutionized the non-invasive diagnosis oftransthyretin cardiac amyloidosis (ATTR-CM) and markedly increased disease recognition.Although this technique should ideally be applied in patients with a high pre-test probability

Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardialextracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiationof disease-modifying therapies.

Aims Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) basedon the 30-month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). This post-hoc analysisevaluated outcomes in ATTR-ACT and

IMPORTANCE Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disordercaused by destabilization of serum transthyretin (sTTR). Acoramidis, an approved therapythat achieves near-complete (90%) sTTR stabilization, demonstrated clinical benefitthrough month 30 in

BACKGROUNDTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fataldisease. Vutrisiran, a subcutaneously administered RNA interference therapeuticagent, inhibits the production of hepatic transthyretin.METHODSIn this double-blind, randomized trial, we assigned patients with

Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which severalpromising therapies are in development. The diagnosis is frequently delayed or missed because of the limited specificityof echocardiography

Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy – 2024Realização: Departamento de Insuficiência Cardíaca (DEIC) e Grupo de Estudos de Miocardiopatias (GEMIC)da Sociedade Brasileira de Cardiologia (SBC)Coordenadores: Fábio Fernandes

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloidfibrils at the cardiac level. It can be due to rare genetic variants in

This article provides a critical review of the diagnosticvalue of several echocardiographic findings in cardiacamyloidosis (CA). The importance of early andaccurate detection of CA is emphasized, considering itschallenging diagnosis and

Recent-onset cardiomyopathy represents a clinically dynamic and potentially reversible clinical framework of non-ischaemiccardiomyopathy, characterized by high variability in left ventricular (LV) function and arrhythmic risk. This clinical consensusstatement provides a

Background: Cardiac amyloidosis (CA), characterized by a progressive infiltration of amyloid fibrils in cardiac tissue, presents a diagnosticchallenge due to its resemblance to other cardiomyopathies by echocardiography. Although reduced left

A Report of the American College of Cardiology Solution Set Oversight CommitteeEndorsed by the American Association of Neuromuscular & Electrodiagnostic Medicine, Heart FailureSociety of America, and International Society of Amyloidosis.

Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardialextracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiationof disease-modifying therapies.

Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to

This document was created by an American Society of Echocardiography Amyloidosis Taskforce as a practical accompaniment to therecently published multisociety Expert Consensus Recommendationsfor Multimodality Imaging in Cardiac Amyloidosis.1,2 In this

Posicionamento sobre Diagnóstico e Tratamento daAmiloidose Cardíaca – 2021 Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021Realização: Departamento de Insuficiência Cardíaca (DEIC) e Grupo de Estudos em

Position Statement on Multimodality Cardiac Imaging in Patients with Systemic Diseases – 2026Realização: Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC/SBC)Autores do Posicionamento: Viviane Tiemi Hotta,1,2 Isabela Bispo

Dermot Phelan, Patrick Collier, Paaladinesh Thavendiranathan, Zoran B Popovi
c,Mazen Hanna, Juan Carlos Plana, Thomas H Marwick, James D ThomasABSTRACTBackground The diagnosis of cardiac amyloidosis (CA) ischallenging owing to vague symptomatology

Pablo Garcia-Pavia 1,2,3,*†, Esther Gonzalez-Lopez1,2,†, Lisa J. Anderson4,Francesco Cappelli5, Thibaud Damy 6, Marianna Fontana7,Jose Gonzalez-Costello8,9, Ruxandra Jurcut 10,11, Olivier Lairez12,Peter van der Meer 13, Marco Merlo 14,15, Stefano Perlini16,and Antoni

Perry Elliott , MD; Brian M. Drachman, MD; Stephen S. Gottlieb , MD; James E. Hoffman, MD; Scott L. Hummel , MD;Daniel J. Lenihan , MD; Ben Ebede, MS, MBA;

A amiloidose por transtirretina (ATTR) é uma causa rarade cardiomiopatia restritiva e/ou polineuropatia periférica,de caráter progressivo, irreversível e fatal, subdiagnosticadae com diagnóstico definitivo realizado de forma tardia.1O diagnóstico precoce, a

O estudo de Fernandes et al.,1 utilizou dados daCoorte ELSA-BRASIL2,3 e demostrou que em pacientesassintomáticos e sem histórico de doença cardiovascular,medidas ecocardiográficas que fazem parte da rotina diária dequalquer serviço

Fundamento: A amiloidose por transtirretina (ATTR) é uma doença infiltrativa causada pela deposição anormal de proteínaprincipalmente no coração e no sistema nervoso periférico. Quando acomete o coração, a doença manifesta-se

Fundamento: A cardiomiopatia amiloide por transtirretina (TTR) associada à VAL142Ile manifesta-se tipicamente empacientes na sexta ou sétima décadas de vida, sendo uma das formas mais comuns de amiloidose cardíaca hereditária.Estudo

A prevalência de homozigotos para a variante genéticaVal142Ile no gene da transtirretina (TTR) é extremamentebaixa na população geral (0,72%) e um pouco maior emestudos de biópsia endomiocárdica (de 6% a